NCT06618872 Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
| NCT ID | NCT06618872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Dementia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-12-03 |
| Primary Completion | 2027-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2024-12-03 with a primary completion date of 2027-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to investigate the clinical validity of tau-PET with \[18F\]RO948 vs. amyloid-PET in patients with Mild Cognitive Impairment (MCI) or mild dementia
Eligibility Criteria
Inclusion Criteria: * Written Inform Consent to participating. * 50 to 85 years of age * a diagnosis of Mild Cognitive Impairment (MCI=at least one pathological neuropsychological test but no functional impairment based on the Amsterdam IADL score) or mild dementia (both cognitive and functional impairments) * availability of MRI within 6 months before screening * prescription of a diagnostic amyloid PET * Willing and able to comply with the requirements of the study, as judged by the investigator. Exclusion Criteria: * The presence of psychiatric disorders, extensive white matter lesions or other stigmata of vascular dementia. * Visual and auditory acuity inadequate for neuropsychological testing. * Enrolment in previous clinical trials for AD potentially affecting amyloid and/or tau brain load * Enrolment in other trials or studies not compatible with \[18F\]RO948 Imaging study. * Ferromagnetic implants and devices (including implants or devices held in place by sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not eligible for MRI scanning. * Women of childbearing potential must not be pregnant (negative urine β-hCG on the day of imaging) or breast feeding at screening
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06618872 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06618872 currently recruiting?
Yes, NCT06618872 is actively recruiting participants. Contact the research team at valentina.garibotto@hug.ch for enrollment information.
Where is the NCT06618872 trial being conducted?
This trial is being conducted at Geneva, Switzerland, Lausanne, Switzerland.
Who is sponsoring the NCT06618872 clinical trial?
NCT06618872 is sponsored by University Hospital, Geneva. The trial plans to enroll 120 participants.